RxSight, Inc. (RXST)

Market Cap	246.31M -58.6%
Revenue (ttm)	127.48M -14.0%
Net Income	-46.64M
EPS	-1.14
Shares Out	41.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,139
Open	5.85
Previous Close	5.95
Day's Range	5.80 - 6.27
52-Week Range	n/a
Beta	1.23
Analysts	Hold
Price Target	n/a
Earnings Date	May 6, 2026

About RXST

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 461
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST
• Website: https://rxsight.com

Financial Performance

In 2025, RxSight's revenue was $134.48 million, a decrease of -3.89% compared to the previous year's $139.93 million. Losses were -$38.94 million, 41.8% more than in 2024.